Transcatheter aortic valve replacement

Comprehensive review and present status

Sameer Arora, Jacob A Misenheimer, Radhakrishnan Ramaraj

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Aortic stenosis is the most common valvular heart disease in the developed world. About 7% of the population over age 65 years suffers from degenerative aortic stenosis. The prognosis of patients with symptomatic severe aortic stenosis is dismal without valve replacement. Even though the American College of Cardiology recommends aortic valve replacement to treat this condition as a class I recommendation, approximately one third of these patients over the age of 75 years are not referred for surgery. Typically, this is from concern about prohibitive surgical risk associated with patient frailty, comorbidities, age, and severe left ventricular dysfunction. The advent in France of transcatheter aortic valve replacement has raised the hope in the United States for an alternative, less invasive treatment for aortic stenosis. Two recent trials—the Placement of AoRTic TraNscathetER Valve Trial Edwards SAPIEN Transcatheter Heart Valve (PARTNER) and the CoreValve US Pivotal—have established transcatheter aortic valve replacement as the preferred approach in patients who are at high or prohibitive surgical risk. The more recently published PARTNER 2 trial has shown the feasibility of transcatheter aortic valve replacement in intermediate-surgical-risk patients as well. With a profile that promises easier use and better valve performance and delivery, newer-generation valves have shown their potential for further improvement in safety profile and overall out-comes. We review the history and status of this topic.

Original languageEnglish (US)
Pages (from-to)29-38
Number of pages10
JournalTexas Heart Institute Journal
Volume44
Issue number1
DOIs
StatePublished - Feb 1 2017

Fingerprint

Aortic Valve Stenosis
Aortic Valve
Heart Valve Diseases
Heart Valves
Left Ventricular Dysfunction
France
Comorbidity
History
Transcatheter Aortic Valve Replacement
Safety
Population
Therapeutics

Keywords

  • Age factors
  • Aortic valve insufficiency/therapy
  • Aortic valve stenosis/mortality/surgery
  • Evaluation studies as topic
  • Heart valve diseases/therapy
  • Heart valve prosthesis implantation/adverse effects/instrumentation
  • Postoperative complications/prevention & control
  • Prosthesis design/trends
  • Transcatheter aortic valve replacement/mortality/trends
  • Treatment outcome

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Transcatheter aortic valve replacement : Comprehensive review and present status. / Arora, Sameer; Misenheimer, Jacob A; Ramaraj, Radhakrishnan.

In: Texas Heart Institute Journal, Vol. 44, No. 1, 01.02.2017, p. 29-38.

Research output: Contribution to journalReview article

Arora, Sameer ; Misenheimer, Jacob A ; Ramaraj, Radhakrishnan. / Transcatheter aortic valve replacement : Comprehensive review and present status. In: Texas Heart Institute Journal. 2017 ; Vol. 44, No. 1. pp. 29-38.
@article{20dbe7db343d42e3b0faf844c7a1932f,
title = "Transcatheter aortic valve replacement: Comprehensive review and present status",
abstract = "Aortic stenosis is the most common valvular heart disease in the developed world. About 7{\%} of the population over age 65 years suffers from degenerative aortic stenosis. The prognosis of patients with symptomatic severe aortic stenosis is dismal without valve replacement. Even though the American College of Cardiology recommends aortic valve replacement to treat this condition as a class I recommendation, approximately one third of these patients over the age of 75 years are not referred for surgery. Typically, this is from concern about prohibitive surgical risk associated with patient frailty, comorbidities, age, and severe left ventricular dysfunction. The advent in France of transcatheter aortic valve replacement has raised the hope in the United States for an alternative, less invasive treatment for aortic stenosis. Two recent trials—the Placement of AoRTic TraNscathetER Valve Trial Edwards SAPIEN Transcatheter Heart Valve (PARTNER) and the CoreValve US Pivotal—have established transcatheter aortic valve replacement as the preferred approach in patients who are at high or prohibitive surgical risk. The more recently published PARTNER 2 trial has shown the feasibility of transcatheter aortic valve replacement in intermediate-surgical-risk patients as well. With a profile that promises easier use and better valve performance and delivery, newer-generation valves have shown their potential for further improvement in safety profile and overall out-comes. We review the history and status of this topic.",
keywords = "Age factors, Aortic valve insufficiency/therapy, Aortic valve stenosis/mortality/surgery, Evaluation studies as topic, Heart valve diseases/therapy, Heart valve prosthesis implantation/adverse effects/instrumentation, Postoperative complications/prevention & control, Prosthesis design/trends, Transcatheter aortic valve replacement/mortality/trends, Treatment outcome",
author = "Sameer Arora and Misenheimer, {Jacob A} and Radhakrishnan Ramaraj",
year = "2017",
month = "2",
day = "1",
doi = "10.14503/THIJ-16-5852",
language = "English (US)",
volume = "44",
pages = "29--38",
journal = "Texas Heart Institute Journal",
issn = "0730-2347",
publisher = "Texas Heart Institute",
number = "1",

}

TY - JOUR

T1 - Transcatheter aortic valve replacement

T2 - Comprehensive review and present status

AU - Arora, Sameer

AU - Misenheimer, Jacob A

AU - Ramaraj, Radhakrishnan

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Aortic stenosis is the most common valvular heart disease in the developed world. About 7% of the population over age 65 years suffers from degenerative aortic stenosis. The prognosis of patients with symptomatic severe aortic stenosis is dismal without valve replacement. Even though the American College of Cardiology recommends aortic valve replacement to treat this condition as a class I recommendation, approximately one third of these patients over the age of 75 years are not referred for surgery. Typically, this is from concern about prohibitive surgical risk associated with patient frailty, comorbidities, age, and severe left ventricular dysfunction. The advent in France of transcatheter aortic valve replacement has raised the hope in the United States for an alternative, less invasive treatment for aortic stenosis. Two recent trials—the Placement of AoRTic TraNscathetER Valve Trial Edwards SAPIEN Transcatheter Heart Valve (PARTNER) and the CoreValve US Pivotal—have established transcatheter aortic valve replacement as the preferred approach in patients who are at high or prohibitive surgical risk. The more recently published PARTNER 2 trial has shown the feasibility of transcatheter aortic valve replacement in intermediate-surgical-risk patients as well. With a profile that promises easier use and better valve performance and delivery, newer-generation valves have shown their potential for further improvement in safety profile and overall out-comes. We review the history and status of this topic.

AB - Aortic stenosis is the most common valvular heart disease in the developed world. About 7% of the population over age 65 years suffers from degenerative aortic stenosis. The prognosis of patients with symptomatic severe aortic stenosis is dismal without valve replacement. Even though the American College of Cardiology recommends aortic valve replacement to treat this condition as a class I recommendation, approximately one third of these patients over the age of 75 years are not referred for surgery. Typically, this is from concern about prohibitive surgical risk associated with patient frailty, comorbidities, age, and severe left ventricular dysfunction. The advent in France of transcatheter aortic valve replacement has raised the hope in the United States for an alternative, less invasive treatment for aortic stenosis. Two recent trials—the Placement of AoRTic TraNscathetER Valve Trial Edwards SAPIEN Transcatheter Heart Valve (PARTNER) and the CoreValve US Pivotal—have established transcatheter aortic valve replacement as the preferred approach in patients who are at high or prohibitive surgical risk. The more recently published PARTNER 2 trial has shown the feasibility of transcatheter aortic valve replacement in intermediate-surgical-risk patients as well. With a profile that promises easier use and better valve performance and delivery, newer-generation valves have shown their potential for further improvement in safety profile and overall out-comes. We review the history and status of this topic.

KW - Age factors

KW - Aortic valve insufficiency/therapy

KW - Aortic valve stenosis/mortality/surgery

KW - Evaluation studies as topic

KW - Heart valve diseases/therapy

KW - Heart valve prosthesis implantation/adverse effects/instrumentation

KW - Postoperative complications/prevention & control

KW - Prosthesis design/trends

KW - Transcatheter aortic valve replacement/mortality/trends

KW - Treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=85013413984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013413984&partnerID=8YFLogxK

U2 - 10.14503/THIJ-16-5852

DO - 10.14503/THIJ-16-5852

M3 - Review article

VL - 44

SP - 29

EP - 38

JO - Texas Heart Institute Journal

JF - Texas Heart Institute Journal

SN - 0730-2347

IS - 1

ER -